

Supplementary Figure 1. Plot of DMFS and OS for all patients according to the densities of CD45RO+ cells (A, B), CD8+ cells (C, D), and CD3+ cells (E, F) in combined tumor regions (CT and IM) (n = 288). For each marker, high densities in the CT and IM (HiHi, red curve), low densities in the CT and IM (LoLo, blue curve), and heterogeneous densities with CT^{Lo} and IM^{Hi} or CT^{Hi} plus IM^{Lo} (Het, green curve) are presented, respectively.

CT, center of the tumor; DMFS, distant metastasis-free survival; IM, invasive margin; OS, overall survival.

Study	Patients	T-cell subtype	Compartment	Localization	Main findings
				(CT vs IM)	
Schalper et al.[19]	552 pts Stage I-IV	CD3, CD8, CD20	Intraepithelial, stromal and total	No	CD8+ TILs have independent positive PI.
Donnem et al.[21]	797 pts Stage I-IIIA	CD8	Stromal	Yes, only in one cohort (178 pts)	Stromal CD8+ T cells have independent positive PI and were candidate for TNM-Immunoscore.
Paulsen et al.[22]	536 pts Stage I-IIIA	CD45RO, CD8	Intraepithelial, stromal	No	In SCC group, intraepithelial CD45RO+ TILs have independent positive PI and combining the intraepithelial CD45RO score with stromal CD8 score, the PI increased.
Ishii et al.[32]	36 pts Stage II-III	CD3, CD8	No	Yes	IS (CD3+ and CD8+ TILs in CT and IM) have positive PI.

Supplementary Table 1. Previous studies on the association of TILs with clinical outcome and establishment of IS in NSCLC

TILs, tumor infiltrating lymphocytes; IS, immunoscore; CT, center of the tumor; IM, invasive margin; PI, prognostic impact; SCC, squamous cell carcinoma.